Innovation in the Fight Against Parkinson's: Stimvia's Non-Invasive URIS® Therapy Shows Success in Clinical Study

OSTRAVA, Czech Republic, Aug. 19, 2025 /PRNewswire/ -- Stimvia, a medtech company based in the Czech Republic, has successfully completed a clinical study on peroneal electrical transcutaneous neuromodulation (peroneal eTNM®) through its URIS® device to treat Parkinson's disease symptoms. Results, published in Clinical Parkinsonism & Related Disorders, confirm the safety of this non-invasive treatment and suggest a positive impact on symptom relief, particularly tremor, and patients' quality of life.

"Patients experienced visible improvements not only in motor symptoms like resting tremor, but more importantly in their everyday comfort and well-being. The changes in quality-of-life questionnaires exceeded the threshold of clinical relevance. And most importantly—there were no severe side effects," says Prof. MUDr. David Skoloudik, Ph.D., FESO, FEAN, principal investigator of the study and Vice Dean for Science and Research at the Faculty of Medicine, University of Ostrava.

The study included 12 Parkinson's patients taking Levodopa, a medication that alleviates symptoms but tends to lose effectiveness over time, producing more side effects. The goal was to determine whether URIS® could serve as a meaningful complement to standard treatment.

Over six weeks, participants used the URIS® device for daily 30-minute stimulation of the peroneal nerve behind the knee, followed by six weeks without stimulation to observe if the positive effects would persist. The greatest benefits were reported in daily functioning: patients experienced less discomfort, improved ability to perform activities, and an overall increase in quality of life—especially due to a significant reduction in tremor. These improvements surpassed the clinically significant threshold, meaning they had a real, measurable impact on patients.

"With the combination of Levodopa and non-invasive neuromodulation, we aim to slow the progression of the disease and extend patients' quality years of life—without the need for invasive procedures such as deep brain stimulation. We're already seeing that URIS® may be a more suitable option in the early stages of Parkinson's, thanks to its non-invasive nature, ease of home use, and strong safety profile," says Lukas Doskocil, CEO of Stimvia.

An indicator of the therapy's value, according to Stimvia, is that after the, 80% of the patients from the pilot study voluntarily chose to continue using URIS® therapy after the initial phase. Stimvia is now preparing a larger international clinical trial this fall to confirm these promising results.

Logo - https://mma.prnewswire.com/media/2033771/4748122/Stimvia_Logo.jpg

SOURCE Stimvia